According to a recent survey, hereditary angioedema is a rare genetic disorder that affects approximately 1 in 50,000 people worldwide. It is characterized by recurrent episodes of swelling in the skin and mucous membranes, which can be painful and potentially life-threatening if they occur in the airways or digestive tract. The condition results from a deficiency or dysfunction of C1 inhibitor protein, which regulates immune system activity and prevents excess fluid from leaking out of blood vessels into surrounding tissues. Symptoms may first appear during childhood or adolescence and often worsen over time without proper treatment. There are currently several medications available to prevent attacks or treat acute symptoms, including plasma-derived C1 inhibitor replacement therapy, bradykinin receptor antagonists, and kallikrein inhibitors. However, many patients still struggle to obtain prompt diagnosis and access to these treatments due to limited awareness among healthcare providers and high costs associated with their use. Ongoing research efforts are focused on improving diagnostic accuracy, developing new therapies with longer duration of action or better tolerability profiles than existing options, and exploring potential links between hereditary angioedema and other inflammatory conditions such as autoimmune disease or cancer.
1.
Trial Questions Role of Dual Immunotherapy in First-Line NSCLC
2.
Transplantation Fails to Improve Survival in Mantle Cell Lymphoma
3.
In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.
4.
PSMA PET Beats MRI in Prostate Cancer Staging Study
5.
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor
1.
Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence
2.
Multiple Primary Lung Cancer: Multidisciplinary Advances in Diagnosis and Care
3.
Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment
4.
Advancements in Breast Cancer Treatment: From Chemotherapy to Immunotherapy
5.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Navigating the Complexities of Ph Negative ALL - Part VIII
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation